Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Tanshinone IIA Sulfonate plus hydration to prevent contrast-induced acute kidney injury after PCI
ChiCTR2300070064Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Henan University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sodium tanshinone IIA sulfonate in contrast-induced nephropathy (CIN) (2 arms), sponsored by The First Affiliated Hospital of Henan University. Primary endpoints: Serum creatinine and Cystatin C. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
sodium tanshinone IIA sulfonate
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR2300070064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070064.